Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alfred Guirguis

Gynecologic Oncology Oak Lawn, IL Doctor of Osteopathy

NPI 1063539211 CMS profile 275390

6700 W 95Th St, Suite 330, Oak Lawn, IL 60453

Open in the dashboard

General payments

$43,887

231 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$42,041 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Alfred Guirguis of Oak Lawn, IL is reported in the CMS Open Payments database as having received $43,887 across 231 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $42,041 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,100 34
2024 General $885 35
2023 General $1,455 35
2022 General $7,414 34
2021 General $1,647 26
2020 General $22,593 30
2019 General $8,793 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alfred Guirguis
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Alfred Guirguis were reported at $1,100. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Alfred Guirguis Gynecologic Oncology median Middle half National median
2019 $8,793 $287 $113–$1,548 $163
2020 $22,593 $223 $59–$2,164 $114
2021 $1,647 $193 $68–$1,139 $132
2022 $7,414 $252 $90–$1,151 $149
2023 $1,455 $281 $102–$1,419 $160
2024 $885 $308 $108–$1,502 $164
2025 $1,100 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Baxter Healthcare $17,377 18 payments
  2. AstraZeneca Pharmaceuticals LP $15,194 38 payments
  3. Seattle Genetics, Inc. $6,899 16 payments
  4. Intuitive Surgical, Inc. $918 7 payments
  5. Merck Sharp & Dohme Corporation $876 40 payments
  6. Eisai Inc. $408 21 payments
  7. GlaxoSmithKline, LLC. $323 12 payments
  8. Amgen Inc. $221 10 payments
  9. Clovis Oncology, Inc. $209 12 payments
  10. Amneal Pharmaceuticals LLC $185 7 payments
  11. Other $1,276 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,323 11 payments
  2. Food and Beverage $5,494 200 payments
  3. Consulting Fee $3,491 1 payment
  4. Travel and Lodging $2,403 15 payments
  5. Education $176 4 payments
Products named General payments · program years 2019–2025
  1. FLOSEAL $16,912 10 payments
  2. TISSEEL $16,333 7 payments
  3. LYNPARZA Oncology $15,194 38 payments
  4. TIVDAK $6,978 20 payments
  5. KEYTRUDA $681 31 payments
  6. Da Vinci Surgical System $665 5 payments
  7. Lenvima $408 21 payments
  8. LYNPARZA Oncology $351 18 payments
  9. JEMPERLI $323 12 payments
  10. ZEJULA $323 12 payments
  11. Other $2,724 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

190

Median for Gynecological Oncology: 95

Drug cost

$3,361

Median for Gynecological Oncology: $4,719

Branded share of claims

34.2%

Median for Gynecological Oncology: 19.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enoxaparin Sodium Generic 23 $2,235
Dexamethasone Generic 19 $389
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 65 $357
Ibuprofen Generic 55 $213
Gabapentin Generic 15 $148
Tramadol Hcl Generic 13 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$1,093,713

Of which drugs: $935,029

Medicare patients

307

Average age 74

Services billed

36,839

307 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 58%
Arthritis 45%
Diabetes 28%
Chronic kidney disease 24%
Depression 24%
Ischemic heart disease 22%
Osteoporosis 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, pembrolizumab, 1 mg J9271 Office 13 9,000 $402,648
Injection, eflapegrastim-xnst, 0.1 mg J1449 Office 12 1,848 $38,789
Injection, fosnetupitant 235 mg and palonosetron 0.25 mg J1454 Office 17 44 $22,930
Injection, carboplatin, 50 mg J9045 Office 15 298 $821
Injection, paclitaxel, 1 mg J9267 Office 11 6,314 $515
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 31 1,358 $118
Infusion, normal saline solution , 1000 cc J7030 Office 17 42 $87
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 19 49 $32
Injection, ondansetron hydrochloride, per 1 mg J2405 Office 13 288 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $115
  • Merck Sharp & Dohme Corporation $56
$171 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $146
$146 — —
JEMPERLI
  • GlaxoSmithKline, LLC. $83
$83 — —
ZEJULA
  • GlaxoSmithKline, LLC. $83
$83 — —
AVASTIN
  • Amneal Pharmaceuticals LLC $79
$79 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

231 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record